Terms: = Breast cancer AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
9 results:
1. Preclinical and Dose-Finding Phase I Trial Results of Combined treatment with a torc1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
[TBL] [Abstract] [Full Text] [Related]
2.
Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
[TBL] [Abstract] [Full Text] [Related]
3. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract] [Full Text] [Related]
4. treatment of Triple-Negative breast cancer with torc1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent cancer Stem Cell Population.
Bhola NE; Jansen VM; Koch JP; Li H; Formisano L; Williams JA; Grandis JR; Arteaga CL
Cancer Res; 2016 Jan; 76(2):440-52. PubMed ID: 26676751
[TBL] [Abstract] [Full Text] [Related]
5. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract] [Full Text] [Related]
6. Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in breast cancer Cells Only When Grown in Nutrient-Poor Conditions.
Silvestri A; Palumbo F; Rasi I; Posca D; Pavlidou T; Paoluzi S; Castagnoli L; Cesareni G
PLoS One; 2015; 10(8):e0136250. PubMed ID: 26291325
[TBL] [Abstract] [Full Text] [Related]
7. mtorc1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract] [Full Text] [Related]
8. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract] [Full Text] [Related]
9. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.
Horak P; Crawford AR; Vadysirisack DD; Nash ZM; DeYoung MP; Sgroi D; Ellisen LW
Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4675-80. PubMed ID: 20176937
[TBL] [Abstract] [Full Text] [Related]
